[go: up one dir, main page]

MX2018003062A - Receptores de celula t que reconocen kras mutante restringido en hla-cw8. - Google Patents

Receptores de celula t que reconocen kras mutante restringido en hla-cw8.

Info

Publication number
MX2018003062A
MX2018003062A MX2018003062A MX2018003062A MX2018003062A MX 2018003062 A MX2018003062 A MX 2018003062A MX 2018003062 A MX2018003062 A MX 2018003062A MX 2018003062 A MX2018003062 A MX 2018003062A MX 2018003062 A MX2018003062 A MX 2018003062A
Authority
MX
Mexico
Prior art keywords
hla
restricted
cell receptors
kras mutant
mammal
Prior art date
Application number
MX2018003062A
Other languages
English (en)
Inventor
A Rosenberg Steven
LU Yong-chen
tran Eric
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MX2018003062A publication Critical patent/MX2018003062A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G01N33/57575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describe un receptor de célula T (TCR) aislado o purificado que tiene especificidad antigénica por el homólogo del oncogén viral del sarcoma de rata de Kirsten (KRAS) presentado en el contexto de una molécula HLA-Cw*0802. También son proporcionados polipéptidos y proteínas relacionados, así como ácidos nucleicos, vectores de expresión recombinantes, células anfitrionas, poblaciones de células y composiciones farmacéuticas relacionadas. También se describen métodos de detección de la presencia de cáncer en un mamífero y métodos de tratamiento o prevención del cáncer en un mamífero.
MX2018003062A 2015-09-15 2016-09-09 Receptores de celula t que reconocen kras mutante restringido en hla-cw8. MX2018003062A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562218688P 2015-09-15 2015-09-15
PCT/US2016/050875 WO2017048593A1 (en) 2015-09-15 2016-09-09 T cell receptors recognizing hla-cw8 restricted mutated kras

Publications (1)

Publication Number Publication Date
MX2018003062A true MX2018003062A (es) 2018-09-11

Family

ID=56985686

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003062A MX2018003062A (es) 2015-09-15 2016-09-09 Receptores de celula t que reconocen kras mutante restringido en hla-cw8.

Country Status (13)

Country Link
US (3) US10556940B2 (es)
EP (2) EP3901169B1 (es)
JP (2) JP7185524B2 (es)
KR (2) KR20250117744A (es)
CN (2) CN115073583A (es)
AU (3) AU2016323017B2 (es)
DK (1) DK3350213T3 (es)
ES (1) ES2879287T3 (es)
IL (1) IL257840B2 (es)
MX (1) MX2018003062A (es)
SA (1) SA518391109B1 (es)
SG (1) SG10201913868XA (es)
WO (1) WO2017048593A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017023801A1 (en) 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Intracellular genomic transplant and methods of therapy
SG11201900654QA (en) 2016-08-02 2019-02-27 Us Health Anti-kras-g12d t cell receptors
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
EP4234576A3 (en) * 2017-03-31 2023-09-13 The United States of America, as represented by the Secretary, Department of Health and Human Services Methods of isolating neoantigen-specific t cell receptor sequences
EP3635000A4 (en) * 2017-05-16 2021-04-14 The Johns Hopkins University Manabodies and methods of using
CN111511375A (zh) 2017-06-30 2020-08-07 因提玛生物科学公司 用于基因治疗的腺相关病毒载体
US11306132B2 (en) 2017-09-20 2022-04-19 The United States Of America, As Represented By The Secretary Department Of Health And Human Services HLA class II-restricted T cell receptors against mutated RAS
KR102757789B1 (ko) 2017-10-05 2025-01-20 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 쥐 불변 영역을 갖는 tcr을 발현하는 세포를 선택적으로 확대시키는 방법
CN119162251A (zh) 2017-12-04 2024-12-20 美国卫生和人力服务部 针对突变的ras的hla i类限制性t细胞受体
TW202015719A (zh) * 2018-06-19 2020-05-01 美商尼恩醫療公司 新抗原及其用途
WO2020037239A1 (en) * 2018-08-16 2020-02-20 Neon Therapeutics, Inc. T cell receptor constructs and uses thereof
CA3127096A1 (en) * 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted t cell receptors against ras with g12r mutation
KR20210130189A (ko) 2019-02-20 2021-10-29 프레드 헛친슨 켄서 리서치 센터 Ras 신항원에 특이적인 결합 단백질 및 이의 용도
US20220175899A1 (en) * 2019-04-11 2022-06-09 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer
CN110172089B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
CN114175087A (zh) * 2019-08-14 2022-03-11 日本电气株式会社 信息处理装置、信息处理方法和记录介质
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
EP4077641A1 (en) 2019-12-20 2022-10-26 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
WO2021163477A1 (en) * 2020-02-14 2021-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against ras with g12v mutation
CN111574616B (zh) * 2020-06-17 2021-02-02 深圳豪石生物科技有限公司 分离的t细胞受体和应用
KR20230046294A (ko) * 2020-07-16 2023-04-05 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 G12v 돌연변이를 갖는 ras에 대한 hla 클래스 ii-제한된 drb t 세포 수용체
WO2022072760A1 (en) * 2020-10-02 2022-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
JP2024507929A (ja) 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
CN114920824B (zh) * 2022-05-27 2023-12-05 重庆医科大学 Tcr或其抗原结合片段及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301017B2 (en) * 2002-05-30 2007-11-27 Kolesnick Richard N Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
ES2842878T3 (es) * 2005-08-05 2021-07-15 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Generación de células T específicas de antígeno
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
PT2618835T (pt) * 2010-09-20 2017-08-08 Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Epítopos de célula t e recetores de célula t específicos de antigénio
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
PT3392270T (pt) * 2011-09-15 2020-11-24 Us Health Recetores de células t que reconhecem mage restrito a hlaa1 ou hla-cw7
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
JP6863893B2 (ja) 2014-11-26 2021-04-21 アメリカ合衆国 抗突然変異ｋｒａｓ ｔ細胞受容体

Also Published As

Publication number Publication date
US10556940B2 (en) 2020-02-11
JP7461445B2 (ja) 2024-04-03
JP2023025108A (ja) 2023-02-21
IL257840B1 (en) 2023-06-01
AU2016323017A1 (en) 2018-04-05
US11667692B2 (en) 2023-06-06
CN108350059A (zh) 2018-07-31
DK3350213T3 (da) 2021-06-21
AU2022209229B2 (en) 2024-05-23
SA518391109B1 (ar) 2022-02-14
JP7185524B2 (ja) 2022-12-07
JP2018535647A (ja) 2018-12-06
EP3350213A1 (en) 2018-07-25
AU2021200833B2 (en) 2022-04-28
US20190040111A1 (en) 2019-02-07
SG10201913868XA (en) 2020-03-30
EP3901169B1 (en) 2026-01-28
ES2879287T3 (es) 2021-11-22
US20230406904A1 (en) 2023-12-21
AU2016323017B2 (en) 2020-11-12
CN108350059B (zh) 2021-10-08
IL257840A (en) 2018-04-30
KR20180044428A (ko) 2018-05-02
EP3350213B1 (en) 2021-03-31
US20200148739A1 (en) 2020-05-14
EP3901169A1 (en) 2021-10-27
AU2021200833A1 (en) 2021-03-04
IL257840B2 (en) 2023-10-01
WO2017048593A1 (en) 2017-03-23
KR20250117744A (ko) 2025-08-05
AU2022209229A1 (en) 2022-09-15
KR102841067B1 (ko) 2025-08-01
CA2998869A1 (en) 2017-03-23
CN115073583A (zh) 2022-09-20
HK1257902A1 (en) 2019-11-01

Similar Documents

Publication Publication Date Title
MX2018003062A (es) Receptores de celula t que reconocen kras mutante restringido en hla-cw8.
MX2020003117A (es) Receptores de celulas t restringidas a hla de clase ii contra ras mutado.
MX2020003504A (es) Receptores de celulas t que reconocen p53 mutado.
MX2017006865A (es) Receptores de células t de kras anti-mutado.
MX2020005765A (es) Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
CY1122720T1 (el) Υποδοχεις τ κυτταρων που αναγνωριζουν περιορισμενη μαgε-α3 μηc ταξης ii
MX2016015383A (es) Receptores de celulas t anti - papilomavirus 16 e7 humano.
MX2021015877A (es) Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.
CY1124176T1 (el) Προβλεψη ανοσογονiκοτητας των επιτοπων των t κυτταρων
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
MX2017014822A (es) Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
CY1118970T1 (el) Στελεχη shigella με υπερφλυκταινωση
BR112019007100A2 (pt) composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
CY1121466T1 (el) Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης
MX378905B (es) Pestivirus.
MX383506B (es) Parvovirus porcino.
CY1125328T1 (el) Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων
AR110503A1 (es) Receptores de células t de apareamiento mejorado